Silence Therapeutics plc (FRA:XRP2)
Germany · Delayed Price · Currency is EUR 5.55
-0.10 (-1.77%)
At close: Dec 1, 2025
Silence Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 25.83 | 43.26 | 31.64 | 21.66 | 16.81 | 7.48 | Upgrade | |
Revenue Growth (YoY) | 40.39% | 36.71% | 46.12% | 28.82% | 124.73% | 2214.81% | Upgrade |
Cost of Revenue | 2.24 | 11.81 | 12.87 | 13.46 | 10.1 | 5.14 | Upgrade |
Gross Profit | 23.59 | 31.45 | 18.78 | 8.19 | 6.71 | 2.34 | Upgrade |
Selling, General & Admin | 24.15 | 26.88 | 26.22 | 25.68 | 27.09 | 19.09 | Upgrade |
Research & Development | 69.42 | 54.15 | 44.99 | 33.73 | 41.66 | 27.59 | Upgrade |
Other Operating Expenses | - | - | - | - | - | -2.04 | Upgrade |
Operating Expenses | 93.58 | 81.03 | 71.21 | 59.41 | 68.75 | 44.65 | Upgrade |
Operating Income | -69.99 | -49.58 | -52.43 | -51.22 | -62.03 | -42.3 | Upgrade |
Interest Expense | - | - | - | - | -0.01 | -0.02 | Upgrade |
Interest & Investment Income | - | - | - | - | 0.01 | 0.18 | Upgrade |
Currency Exchange Gain (Loss) | 3.46 | 0.65 | -2.64 | 1.29 | -0.06 | -7.06 | Upgrade |
Other Non Operating Income (Expenses) | 3.64 | 4.47 | 1.8 | 0.28 | - | - | Upgrade |
EBT Excluding Unusual Items | -62.88 | -44.46 | -53.27 | -49.65 | -62.09 | -49.21 | Upgrade |
Pretax Income | -64.21 | -44.46 | -53.27 | -49.65 | -62.09 | -49.21 | Upgrade |
Income Tax Expense | 0.34 | 0.85 | 0.96 | 0.69 | -8.73 | -4.77 | Upgrade |
Net Income | -64.54 | -45.31 | -54.23 | -50.33 | -53.36 | -44.44 | Upgrade |
Net Income to Common | -64.54 | -45.31 | -54.23 | -50.33 | -53.36 | -44.44 | Upgrade |
Shares Outstanding (Basic) | 48 | 46 | 37 | 32 | 30 | 27 | Upgrade |
Shares Outstanding (Diluted) | 48 | 46 | 37 | 32 | 30 | 27 | Upgrade |
Shares Change (YoY) | 7.98% | 24.69% | 15.21% | 8.58% | 8.78% | 8.85% | Upgrade |
EPS (Basic) | -1.36 | -0.98 | -1.46 | -1.56 | -1.80 | -1.63 | Upgrade |
EPS (Diluted) | -1.36 | -0.98 | -1.46 | -1.56 | -1.80 | -1.63 | Upgrade |
Free Cash Flow | -72.58 | -67.85 | -49.52 | -57.22 | 7.44 | -15.41 | Upgrade |
Free Cash Flow Per Share | -1.53 | -1.47 | -1.33 | -1.78 | 0.25 | -0.56 | Upgrade |
Gross Margin | 91.32% | 72.70% | 59.34% | 37.83% | 39.94% | 31.34% | Upgrade |
Operating Margin | -270.95% | -114.62% | -165.70% | -236.53% | -369.02% | -565.49% | Upgrade |
Profit Margin | -249.86% | -104.74% | -171.37% | -232.44% | -317.44% | -594.03% | Upgrade |
Free Cash Flow Margin | -281.00% | -156.85% | -156.49% | -264.22% | 44.26% | -206.00% | Upgrade |
EBITDA | -69.41 | -48.99 | -51.81 | -50.62 | -61.69 | -41.62 | Upgrade |
EBITDA Margin | -268.70% | -113.25% | -163.74% | -233.78% | - | - | Upgrade |
D&A For EBITDA | 0.58 | 0.59 | 0.62 | 0.6 | 0.34 | 0.68 | Upgrade |
EBIT | -69.99 | -49.58 | -52.43 | -51.22 | -62.03 | -42.3 | Upgrade |
EBIT Margin | -270.95% | -114.62% | -165.70% | -236.53% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.